

Docket No.: PF-0527-1 DIV

By:

Printed:

Adam Sall.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title:

PROSTATE GROWTH-ASSOCIATED MEMBRANE PROTEINS

Serial No.:

09/397,558

Filing Date:

September 16, 1999

Examiner:

Harris, A.

Group Art Unit:

1642

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the aboveidentified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel $\frac{9403}{2}$, Frame $\frac{997}{2}$, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Adam Warwick Bell	Reg. No. 43,490
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Matthew R. Kaser	Reg. No. 44,817
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847



Docket No.: PF-0527-1 DIV

Reg. No. 44,316 Reg. No. 43,168 Reg. No. 45,167 Reg. No. 41,420

Susan K. Sather David G. Streeter Christopher Turner Peng Ben Wang

Please direct all correspondence to:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: Adam Bell , Incyte Genomics, Inc., Phone: (650) 855-0555, Fax: (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE PHARMACEUTICALS, INC.

Date: 22 MAY 2000. By: Lee Bendekgey

Lee Bendekgey

VP, General Counsel/Corporate Secretary

56939

2